masoprocol has been researched along with Multiple Myeloma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donoghue, DJ; McAndrew, CW; Meyer, AN | 1 |
| Amin, S; Anderson, KC; Avet-Loiseau, H; Fulciniti, M; Hideshima, T; Li, C; Minvielle, S; Munshi, NC; Nanjappa, P; Prabhala, R; Rodig, S; Tai, YT; Tassone, P | 1 |
| Deicher, H; Leo, R; Peest, D; Quesada, S | 1 |
3 other study(ies) available for masoprocol and Multiple Myeloma
| Article | Year |
|---|---|
Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
Topics: Apoptosis; Cell Line, Tumor; Fibroblast Growth Factor 2; Golgi Apparatus; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Masoprocol; Multiple Myeloma; Phosphorylation; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; Thanatophoric Dysplasia; Transfection | 2008 |
Significant biological role of sp1 transactivation in multiple myeloma.
Topics: Animals; Apoptosis; Bone Marrow Cells; Cell Cycle; Cell Proliferation; Cell Survival; Gene Knockdown Techniques; Humans; Male; Masoprocol; Melanoma, Experimental; Mice; Mice, SCID; Multiple Myeloma; RNA Interference; Sp1 Transcription Factor; Transcriptional Activation; Tumor Cells, Cultured | 2011 |
Functional and biochemical characteristics of a soluble B lymphocyte proliferation-inhibiting activity produced by bone marrow cells from multiple myeloma patients.
Topics: B-Lymphocytes; Bone Marrow; Humans; Immunosuppressive Agents; Indomethacin; Lymphocyte Activation; Masoprocol; Multiple Myeloma; Solubility; Waldenstrom Macroglobulinemia | 1995 |